Prognostic factors associated with long-term disability and secondary progression in patients with Multiple Sclerosis

被引:16
作者
Ferreira Vasconcelos, Claudia Cristina [1 ]
Kallenbach Aurencao, Juliana Calvet [1 ]
Santos Thuler, Luiz Claudio [2 ,3 ]
Camargo, Solange [4 ]
Alvarenga, Marcos Papais [4 ]
Papais Alvarenga, Regina Maria [1 ,5 ]
机构
[1] Univ Fed Estado Rio de Janeiro, Dept Neurol, Rua Mariz & Banos 775, BR-20270901 Rio De Janeiro, Brazil
[2] Univ Fed Estado Rio de Janeiro, Rua Andre Cavalcanti,37 Ctr, BR-20231050 Rio De Janeiro, RJ, Brazil
[3] Inst Nacl Canc, Rua Andre Cavalcanti,37 Ctr, BR-20231050 Rio De Janeiro, RJ, Brazil
[4] Hosp Fed Lagoa, Dept Neurol, Rua Jardim Bot 501, Rio De Janeiro, Brazil
[5] Hosp Fed Lagoa, Dept Neurol, Rua Mariz & Barms 775, BR-20270901 Rio De Janeiro, Brazil
关键词
Multiple Sclerosis; African Ancestry; Secondary progression; Prognostic factors; Risk factors; Disability; INTRAMUSCULAR INTERFERON BETA-1A; NATURAL-HISTORY; DIAGNOSTIC-CRITERIA; AFRICAN-AMERICANS; DEMYELINATING EVENT; CLINICALLY DEFINITE; GUIDELINES; CONVERSION; DISEASE; LESIONS;
D O I
10.1016/j.msard.2016.03.011
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Predicting the long-term prognosis of patients with multiple sclerosis (MS) remains an uncertain and difficult task, with most data having been obtained exclusively from Caucasian cohorts. Objective: To investigate clinical prognostic factors in a Brazilian mixed-race cohort. Methods: Demographic, clinical and therapeutic factors were investigated in 303 patients with relapsing remitting MS in relation to the following outcomes: time until reaching Expanded Disability Status Scale (EDSS) 3 and EDSS 6, and until secondary progression. Results: Benign course was significantly more frequent among Caucasians when compared to Afro-descendants. Patients with a malignant course had more than one relapse in the first year of the disease and reached EDSS 3 faster if treatment was not started. In the multivariate analysis, the following factors were associated with a significantly shorter time until the established outcomes: male gender, being of African descent, non-recovery after the first relapse, two or more relapses during the first year, a short interval between initial relapses, initial polysymptomatic presentation of pyramidal and cerebellar dysfunction and no treatment prior to reaching EDSS 3. Conclusions: Being of African descent was found to be an unfavorable factor for all outcomes, reinforcing the need to take ethnicity into consideration when defining treatment, particularly in mixed MS populations. (C) 2016 Elsevier B.V. All rights reserved.
引用
收藏
页码:27 / 34
页数:8
相关论文
共 47 条
[1]   A prospective study on the prognosis of multiple sclerosis [J].
M.P. Amato ;
G. Ponziani .
Neurological Sciences, 2000, 21 (Suppl 2) :S831-S838
[2]  
Baghizadeh S, 2013, IRAN J NEUROL, V12, P1
[3]   Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences [J].
Bjartmar, C ;
Trapp, BD .
CURRENT OPINION IN NEUROLOGY, 2001, 14 (03) :271-278
[4]   The window of therapeutic opportunity in multiple sclerosis [J].
Coles, AJ ;
Cox, A ;
Le Page, E ;
Jones, J ;
Trip, SA ;
Deans, J ;
Seaman, S ;
Miller, DH ;
Hale, G ;
Waldmann, H ;
Compston, DA .
JOURNAL OF NEUROLOGY, 2006, 253 (01) :98-108
[5]   Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial [J].
Comi, G. ;
Martinelli, V. ;
Rodegher, M. ;
Moiola, L. ;
Bajenaru, O. ;
Carra, A. ;
Elovaara, I. ;
Fazekas, F. ;
Hartung, H. P. ;
Hillert, J. ;
King, J. ;
Komoly, S. ;
Lubetzki, C. ;
Montalban, X. ;
Myhr, K. M. ;
Ravnborg, M. ;
Rieckmann, P. ;
Wynn, D. ;
Young, C. ;
Filippi, M. .
LANCET, 2009, 374 (9700) :1503-1511
[6]   Effect of early interferon treatment on conversion to definite multiple sclerosis:: a randomised study [J].
Comi, G ;
Filippi, M ;
Barkhof, F ;
Durelli, L ;
Edan, G ;
Fernández, O ;
Hartung, HP ;
Seeldrayers, P ;
Sorensen, PS ;
Rovaris, M ;
Martinelli, V ;
Hommes, OR .
LANCET, 2001, 357 (9268) :1576-1582
[7]   Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial [J].
Comi, Giancarlo ;
De Stefano, Nicola ;
Freedman, Mark S. ;
Barkhof, Frederik ;
Polman, Chris H. ;
Uitdehaag, Bernard M. J. ;
Casset-Semanaz, Florence ;
Hennessy, Brian ;
Moraga, Margaretha Stam ;
Rocak, Sanda ;
Stubinski, Bettina ;
Kappos, Ludwig .
LANCET NEUROLOGY, 2012, 11 (01) :33-41
[8]  
Compston A, 2006, BRAIN, V129, P561, DOI 10.1093/brain/awl034
[9]   Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process [J].
Confavreux, C ;
Vukusic, S ;
Adeleine, P .
BRAIN, 2003, 126 :770-782
[10]   Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis [J].
Cree, BAC ;
Khan, O ;
Bourdette, D ;
Goodin, DS ;
Cohen, JA ;
Marrie, RA ;
Glidden, D ;
Weinstock-Guttman, B ;
Reich, D ;
Patterson, N ;
Haines, JL ;
Pericak-Vance, M ;
DeLoa, C ;
Oksenberg, JR ;
Hauser, SL .
NEUROLOGY, 2004, 63 (11) :2039-2045